BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges ...

“We continue to invest in science as part of our commitment to furthering the medical community's understanding of NUZYRA,” said Randy Brenner, Chief Development and Regulatory Officer of Paratek.

BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today ...